Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bashu Granules is a Traditional Uyghur Medicine (TUM) candidate developed by Xinjiang Huasidan Pharmaceutical Research Co., Ltd. for the treatment of the common cold and influenza. It is specifically indicated for wind-heat syndrome, a traditional diagnostic category characterized by symptoms such as fever, headache, sore throat, and cough. The formulation is a complex herbal mixture, typically including botanical ingredients such as Glycyrrhiza (licorice), Althaea officinalis (marshmallow), and Ziziphus jujuba (jujube), which are processed into a granule form for oral administration. Bashu Granules aims to provide symptomatic relief through its antipyretic, anti-inflammatory, and antitussive properties. The drug has undergone Phase 2 clinical evaluation in China to assess its efficacy and safety in treating upper respiratory tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bashu granules.